← Back to home

NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER)

Clinical trials for NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER) explained in plain language.

Never miss a new study

Get alerted when new NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER) trials appear

Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New combo therapy aims to shrink EGFR lung tumors

Disease control Ongoing

This study tests whether adding the immunotherapy drug ipilimumab to the standard targeted therapy osimertinib is safe and effective for people with a specific type of advanced lung cancer (EGFR-mutated NSCLC). About 24 adults whose cancer is stable on osimertinib will receive th…

Matched conditions: NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER)

Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control

Last updated Jun 12, 2026 12:03 UTC

NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER)

Get alerted when new NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER) trials appear

New combo therapy aims to shrink EGFR lung tumors